Abstract：Objective To preliminarily observe the clinical efficacy of hippocampal-sparing prophylactic cranial irradiation (HS-PCI) using helical tomotherapy (HT) in patients with limited-stage small-cell lung cancer (LS-SCLC) after chemoradiotherapy, and compare HT with intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) in dose distribution. Methods From April to June, 2014, six patients with LS-SCLC who had achieved a complete remission after chemoradiotherapy were assigned to HS-PCI using HT within a month after brain metastasis was ruled out using brain magnetic resonance imaging (MRI). After fusing CT images and MRI images, the hippocampus was contoured in the fusion images and hippocampal avoidance regions were created using a volumetric expansion of 3 mm around the hippocampus. A dose of 25 Gy in 10 fractions to 95% of planning target volume (PTV) was prescribed in HT, IMRT, and VMAT. The clinical efficacy, adverse reactions, neurocognitive function, and brain metastasis were evaluated for HT. The dose distribution in PTV and hippocampus were compared between HT, IMRT, and VMAT. Results There were one patient with abdominal wall and abdominal lymph node metastases, one patient with local recurrence, and no patient with brain metastasis during the observation period. The numbers of patients with grade 1 and grade 2 headache, dizziness, and hair loss reactions were 3 and 1, 3 and 1, and 4 and 2, respectively. There were no significant differences in the average score of the Mini-Mental State Examination before treatment and at 3 and 6 months after treatment (29.7, 29.2, and 29.3;P=0.083, 0.317, and 0.157). The mean dose to the hippocampus was 16.85 Gy for IMRT and 17.59 Gy for VMAT. For HT, the mean doses to the hippocampus and avoidance regions were reduced to 5.26 Gy and 6.21 Gy, respectively. The prescribed dose for HT was reduced by 79% and 71% compared with IMRT and VMAT, respectively. The average coverage rate of the prescribed dose was 94.48% for HT. Conclusions HT achieves promising dose distribution and target coverage in sparing of the hippocampus. Moreover, HT dose not increase the incidence of adverse reactions. The change in neurocognitive function needs to be further studied with long-term observation and large-scale sampling.
Dong Xin,Zhou Zongmei,Miao Junjie et al. Primary clinical study of hippocampal-sparing prophylactic cranial irradiation in limited-stage small-cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2015, 24(2): 131-135.
[1]Aupérin A, Arriagada R, Pignon J P,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission[J]. NEJ Med,1999,341(7):476-484. [2]Sun A, Bae K, Gore EM, et al. Phase Ⅲ trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer:neurocognitive and quality-of-life analysis[J]. J Clin Oncol,2011,29(3):279-286.DOI:10.1200/JCO.2010.29.6053. [3]Eriksson PS, Perfilieva E, Bj rk-Eriksson T,et al. Neurogenesis in the adult human hippocampus[J]. Nat Med,1998,4(11):1313-1317. [4]Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis[J].Science,2003,302(5651):1760-1765. [5]Gondi V, Tomé WA, Mehta MP. Why avoid the hippocampus A comprehensive review[J]. Radiother Oncol,2010,97(3):370-376.DOI:10.1016/j.radonc.2010.09.013. [6]Marsh JC, Herskovic AM, Gielda BT, et al. Intracranial metastatic disease spares the limbic circuit:a review of 697 metastatic lesions in 107 patients[J]. Int J Radiat Oncol Biol Phys,2010,76(2):504-512.DOI:10.1016/j.ijrobp.2009.02.038. [7]Gondi V, Tolakanahalli R, Mehta MP, et al. Hippocampal-sparing whole-brain radiotherapy:a"How-To" technique using helical Tomotherapy and linear accelerator-based intensity-modulated radiotherapy[J]. Int J Radiat Oncol Biol Phys,2010,78(4):1244-1252.DOI:10.1016/j.ijrobp.2010.01.039. [8]Redmond KJ, Mahone EM, Terezakis S, et al. Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children:a prospective study[J]. Neuro Oncol,2013,15(3):360-369.DOI:10.1093/neuonc/nos303. [9]Gondi V, Hermann BP, Mehta MP, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors[J/OL]. Int J Radiat Oncol Biol Phys,2012,83(4):e487-e493[2014-12-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462659/.DOI:10.1016/j.ijrobp.2011.10.021. [10]Blomstrand M, Brodin NP, afRosensch ld PM, et al. Estimated clinical benefit of protecting neurogenesis in the developing brain during radiation therapy for pediatric medulloblastoma[J]. Neuro Oncol,2012,14(7):882-889.DOI:10.1093/neuonc/nos120. [11]Marsh JC, Gielda BT, Herskovic AM, et al. Sparing of the hippocampus and limbic circuit during whole brain radiation therapy:a dosimetric study using helical tomotherapy[J]. J Med Imag Radiat Oncol,2010,54(4):375-382.DOI:10.1111/j.1754-9485.2010.02184.x. [12]Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933):a phase Ⅱ multi-institutional trial[J]. J Clin Oncol,2014,32(34):3810-3816.DOI:10.1200/JCO.2014.57.2909. [13]Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer:short-term health-related quality of life and patient reported symptoms-results of an international phase Ⅲ randomized controlled trial by the EORTC radiation oncology and lung cancer groups[J]. J Clin Oncol,2009,27(1):78-84.DOI:10.1200/JCO.2008.17.0746.
2015, Vol. 24 
